Kit and method for determining prostate cancer malignancy
AssigneeJ-Pharma Co., Ltd.
InventorsNobuyuki Yanagisawa, Isao Okayasu
Life of this patent
Estimating the term…
Loading patent…
AssigneeJ-Pharma Co., Ltd.
InventorsNobuyuki Yanagisawa, Isao Okayasu
Estimating the term…
The present invention relates to kits and methods for determining (diagnosing) prostate cancer malignancy and to predict patient prognoses. Our findings suggested that elevated LAT1 expression in PC is a novel biomarker for high-grade malignancy. Independently of GS, aberrant LAT1 overexpression might be used to screen for aggressive phenotypes of PC that should be treated medically. Prostate biopsies are usually small samples, limiting the evaluation of the tumor area. Thus, LAT1 intensity in prostate biopsy samples may be more a reliable prognostic marker of LP. Especially, we propose LAT1 evaluation against PC with low-risk patients in order to screen who can receive active surveillance. Several LAT1 inhibitors have been found to suppress cancer cell proliferation, so inhibition of LAT1 may be a potential therapeutic strategy for PC and other human cancers.
A method for determining prostate cancer malignancy, comprising:
Dependencies are inferred from the claim text.